GlassScriptPhysician profile
Sherryl B Reed
NPI 1578569984
$14,919.35
in general payments reported to CMS, 2019-2025
49 companies · $1,666 in 2025
The $1,666 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,322 · 2020: $1,843 · 2021: $2,128 · 2022: $2,296 · 2023: $2,595 · 2024: $2,069 · 2025: $1,666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,310 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,310.02 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,570.78 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $1,522.89 | 2019-2025 | |
| Novo Nordisk INC | $1,463.02 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $1,205.05 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $1,192.85 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $669.59 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $663.55 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $600.67 | 2019-2025 | Xifaxan |
| Allergan, INC. | $564.11 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $539.33 | 2019-2024 | Verquvo, Belsomra, Gardasil |
| Pfizer INC. | $536.53 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $502.32 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $457.45 | 2019-2022 | |
| Lilly USA, LLC | $439.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.74 | 2020-2025 | Jardiance, Tradjenta |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherryl Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.